OXiGENE has initiated a phase 2 study of its vascular-disrupting agent ZYBRESTAT (fosbretabulin) for treating patients with polypoidal choroidal vasculopathy (PCV), the company announced in a press release. PCV is a form of choroidal neovascularization characterized by the growth of abnormal blood vessels in the choroid and is similar to wet...